Jerrell Shelton Sells 7,918 Shares of CryoPort (NASDAQ:CYRX) Stock

CryoPort, Inc. (NASDAQ:CYRX) CEO Jerrell Shelton sold 7,918 shares of the business’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $8.00, for a total transaction of $63,344.00. Following the completion of the sale, the chief executive officer owned 1,054,501 shares in the company, valued at $8,436,008. This represents a 0.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

CryoPort Stock Performance

NASDAQ CYRX traded up $0.36 during trading hours on Tuesday, reaching $8.36. The company’s stock had a trading volume of 401,705 shares, compared to its average volume of 429,763. The company’s 50-day moving average is $9.19 and its two-hundred day moving average is $9.36. CryoPort, Inc. has a fifty-two week low of $4.63 and a fifty-two week high of $11.45. The stock has a market cap of $416.83 million, a PE ratio of 6.33 and a beta of 1.69.

CryoPort (NASDAQ:CYRX) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). CryoPort had a negative return on equity of 8.22% and a net margin of 42.35%.The business had revenue of $45.45 million for the quarter, compared to analyst estimates of $42.92 million. Equities analysts expect that CryoPort, Inc. will post -0.99 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CryoPort

Several institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC boosted its stake in CryoPort by 23.8% in the 4th quarter. Millennium Management LLC now owns 3,244,802 shares of the company’s stock worth $31,150,000 after buying an additional 623,896 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of CryoPort by 2.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,858,031 shares of the company’s stock valued at $27,094,000 after acquiring an additional 69,550 shares during the last quarter. Thematics Asset Management lifted its holdings in shares of CryoPort by 12.8% during the 2nd quarter. Thematics Asset Management now owns 1,914,885 shares of the company’s stock worth $14,285,000 after acquiring an additional 216,937 shares during the period. Assenagon Asset Management S.A. lifted its holdings in shares of CryoPort by 37.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,498,774 shares of the company’s stock worth $14,208,000 after acquiring an additional 408,263 shares during the period. Finally, UBS Group AG boosted its position in shares of CryoPort by 6.8% in the fourth quarter. UBS Group AG now owns 1,421,884 shares of the company’s stock worth $13,650,000 after acquiring an additional 90,363 shares during the last quarter. 92.90% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on CYRX shares. Wall Street Zen lowered CryoPort from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Weiss Ratings restated a “sell (d+)” rating on shares of CryoPort in a report on Monday, December 29th. Finally, Needham & Company LLC lifted their price target on shares of CryoPort from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, CryoPort has a consensus rating of “Moderate Buy” and a consensus target price of $12.94.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.